Can chemoprevention reduce the risk of progression to malignancy?
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Falk GW. Barrett’s oesophagus. Gastroenterology 2002; 122: 1569-1591.
- 2. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 2000; 119: 333-338.
- 3. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003; 98: 1931-1939.
- 4. Macdonald CE, Wicks AC, Playford RJ. Final results from 10-year cohort of patients undergoing surveillance for Barrett’s oesophagus: observational study. BMJ 2000; 321: 1252-1255.
- 5. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett’s oesophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001; 96: 3071-3083.
- 6. Triadafilopoulos G. Acid and bile reflux in Barrett’s esophagus: a tale of two evils. Gastroenterology 2001; 121: 1502-1506.
- 7. Souza RF, Spechler SJ. Barrett’s esophagus: chemoprevention. Gastrointest Endosc Clin N Am 2003; 13: 419-432.
- 8. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust 2004; 180: 387-391. <eMJA full text>
- 9. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56.
- 10. Spechler SJ. Disputing dysplasia. Gastroenterology 2001; 120: 1864-1868.
- 11. Richter JE. Antireflux surgery and adenocarcinoma of the esophagus: let the truth be told. Gastroenterology 2001; 121: 1506-1508.
- 12. Bateman DN, Colin-Jones D, Hartz S, et al. Mortality study of 18 000 patients treated with omeprazole. Gut 2003; 52: 942-946.
- 13. Sampliner RE. Long-term endoscopic surveillance of Barrett’s esophagus. Am J Gastroenterol 2003; 98: 1912-1913.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
G S H has acted as a consultant to AstraZeneca, Novartis and Pharmacia (Pfizer), and has received research support, sponsored travel and honoraria for speaking from AstraZeneca, Novartis and Wyeth. S N has acted in an advisory capacity to Pharmacia and has received research support, sponsored travel and honoraria for speaking from AstraZeneca and Pharmacia (Pfizer).